Literature DB >> 26607238

Noninferiority is (too) common in noninferiority trials.

Darius Soonawala1, Olaf M Dekkers2, Jan P Vandenbroucke3, Matthias Egger4.   

Abstract

Mesh：

Year:  2015        PMID： 26607238     DOI： 10.1016/j.jclinepi.2015.11.009

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN： 0895-4356            Impact factor:   6.437


× No keyword cloud information.
  4 in total

1.  Caution: work in progress : While the methodological "revolution" deserves in-depth study, clinical researchers and senior epidemiologists should not be disenfranchised.

Authors:  Miquel Porta; Francisco Bolúmar
Journal:  Eur J Epidemiol       Date:  2016-07-14       Impact factor: 8.082

Review 2.  First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.

Authors:  Shuchi Gulati; Chris Labaki; Georgia Sofia Karachaliou; Toni K Choueiri; Tian Zhang
Journal:  Oncologist       Date:  2022-03-04       Impact factor: 5.837

3.  Design of non-inferiority randomized trials using the difference in restricted mean survival times.

Authors:  Isabelle R Weir; Ludovic Trinquart
Journal:  Clin Trials       Date:  2018-08-03       Impact factor: 2.486

4.  Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.

Authors:  Bishal Gyawali; Frazer A Tessema; Emily H Jung; Aaron S Kesselheim
Journal:  JAMA Netw Open       Date:  2019-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.